CA3158795A1 - Pharmacophore for trail induction - Google Patents

Pharmacophore for trail induction

Info

Publication number
CA3158795A1
CA3158795A1 CA3158795A CA3158795A CA3158795A1 CA 3158795 A1 CA3158795 A1 CA 3158795A1 CA 3158795 A CA3158795 A CA 3158795A CA 3158795 A CA3158795 A CA 3158795A CA 3158795 A1 CA3158795 A1 CA 3158795A1
Authority
CA
Canada
Prior art keywords
compound
formula
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3158795A
Other languages
English (en)
Inventor
Kim D. Janda
Nicholas T. JACOB
Jonathan W. LOCKNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CA3158795A1 publication Critical patent/CA3158795A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3158795A 2014-03-31 2015-03-30 Pharmacophore for trail induction Pending CA3158795A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31
US61/972,689 2014-03-31
CA2944452A CA2944452C (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2944452A Division CA2944452C (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction

Publications (1)

Publication Number Publication Date
CA3158795A1 true CA3158795A1 (en) 2015-10-08

Family

ID=54241169

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3158795A Pending CA3158795A1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction
CA2944452A Active CA2944452C (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2944452A Active CA2944452C (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction

Country Status (20)

Country Link
US (5) US10239877B2 (enExample)
EP (3) EP3125898B1 (enExample)
JP (4) JP6756435B2 (enExample)
KR (2) KR102611067B1 (enExample)
CN (2) CN111499636B (enExample)
AU (5) AU2015241069B2 (enExample)
CA (2) CA3158795A1 (enExample)
CY (1) CY1123093T1 (enExample)
DK (2) DK3125898T3 (enExample)
ES (2) ES2779979T3 (enExample)
FI (1) FI3662910T3 (enExample)
HR (2) HRP20200478T1 (enExample)
HU (2) HUE069651T2 (enExample)
LT (2) LT3125898T (enExample)
PL (2) PL3125898T3 (enExample)
PT (2) PT3125898T (enExample)
RS (2) RS60163B1 (enExample)
SI (2) SI3662910T1 (enExample)
SM (2) SMT202000219T1 (enExample)
WO (1) WO2015153468A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
PL2968294T3 (pl) 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
SMT201900291T1 (it) * 2013-11-15 2019-07-11 Oncoceutics Inc 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidriomidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso
HUE069651T2 (hu) 2014-03-31 2025-03-28 Scripps Research Inst Farmakofór TRAIL indukcióra
SMT202500087T1 (it) * 2015-01-30 2025-03-12 Oncoceutics Inc Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
WO2017132661A2 (en) * 2016-01-29 2017-08-03 Oncoceutics, Inc. G protein-coupled receptor (gpcr) modulation by imipridones
US11091483B2 (en) 2016-08-12 2021-08-17 Madera Therapeutics, LLC Protein kinase regulators
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
AU2020228047B2 (en) 2019-02-27 2025-11-20 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
BR112023002082A2 (pt) 2020-08-06 2023-05-09 Eoetvoes Lorand Tudomanyegyetem Síntese de derivados de imipridona e sua avaliação para sua atividade anticancerígena
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199B (zh) * 2023-06-02 2025-03-18 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途
EP4684834A1 (de) * 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
EP1517904A4 (en) * 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
PT2303264T (pt) * 2008-06-09 2018-05-14 Allergan Inc Métodos de tratamento de condições mediadas adrenérgicas alfa utilizando derivados de imidazolina
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
WO2012078448A1 (en) * 2010-12-06 2012-06-14 Schering Corporation Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
TWI658047B (zh) * 2011-03-15 2019-05-01 吉斯藥品公司 異唑啶衍生物
WO2012138789A2 (en) * 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
RS67757B1 (sr) 2011-04-29 2026-03-31 Penn State Res Found Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
PL2968294T3 (pl) * 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
HUE069651T2 (hu) 2014-03-31 2025-03-28 Scripps Research Inst Farmakofór TRAIL indukcióra

Also Published As

Publication number Publication date
EP4470617A2 (en) 2024-12-04
PL3125898T3 (pl) 2020-11-16
ES2779979T3 (es) 2020-08-21
EP4470617A3 (en) 2025-02-26
KR102611067B1 (ko) 2023-12-06
RS60163B1 (sr) 2020-05-29
US10239877B2 (en) 2019-03-26
EP3125898A4 (en) 2017-08-16
PT3125898T (pt) 2020-04-01
PT3662910T (pt) 2024-11-27
KR20220163533A (ko) 2022-12-09
LT3125898T (lt) 2020-04-10
HUE049013T2 (hu) 2020-08-28
AU2015241069B2 (en) 2020-10-15
US10633385B2 (en) 2020-04-28
AU2015241069A1 (en) 2016-10-20
CA2944452C (en) 2022-07-19
JP6756435B2 (ja) 2020-09-16
CN106456643B (zh) 2020-04-17
PL3662910T3 (pl) 2025-08-11
DK3662910T3 (en) 2024-11-04
US12630550B2 (en) 2026-05-19
AU2024204977B2 (en) 2026-04-16
CN106456643A (zh) 2017-02-22
JP6873201B2 (ja) 2021-05-19
ES2999685T3 (en) 2025-02-26
CN111499636A (zh) 2020-08-07
SMT202400497T1 (it) 2025-01-14
RS66254B1 (sr) 2024-12-31
CY1123093T1 (el) 2021-10-29
US20220002300A1 (en) 2022-01-06
KR20160138513A (ko) 2016-12-05
US20200283440A1 (en) 2020-09-10
US20170107221A1 (en) 2017-04-20
HUE069651T2 (hu) 2025-03-28
SI3125898T1 (sl) 2020-07-31
JP2020002170A (ja) 2020-01-09
JP2017511321A (ja) 2017-04-20
US20190284188A1 (en) 2019-09-19
EP3662910A1 (en) 2020-06-10
JP2021119157A (ja) 2021-08-12
HRP20200478T1 (hr) 2020-07-24
JP2023022184A (ja) 2023-02-14
AU2026206080A1 (en) 2026-07-30
AU2024204977A1 (en) 2024-08-08
US11891392B2 (en) 2024-02-06
DK3125898T3 (da) 2020-03-30
CN111499636B (zh) 2023-01-13
EP3662910B1 (en) 2024-09-18
CA2944452A1 (en) 2015-10-08
EP3125898A1 (en) 2017-02-08
US20240190877A1 (en) 2024-06-13
JP7688245B2 (ja) 2025-06-04
LT3662910T (lt) 2024-12-27
JP7186256B2 (ja) 2022-12-08
WO2015153468A1 (en) 2015-10-08
KR102473930B1 (ko) 2022-12-05
EP3125898B1 (en) 2019-12-25
SI3662910T1 (sl) 2025-05-30
AU2022283729A1 (en) 2023-02-02
HRP20241680T1 (hr) 2025-02-28
SMT202000219T1 (it) 2020-05-08
AU2020286314A1 (en) 2021-01-21
FI3662910T3 (fi) 2024-10-31

Similar Documents

Publication Publication Date Title
AU2024204977B2 (en) Pharmacophore for trail induction
US10258626B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
HK40121084A (en) Pharmacophore for trail induction
HK40020077A (en) Pharmacophore for trail induction
HK40020077B (en) Pharmacophore for trail induction
HK40035689B (en) Pharmacophore for trail induction
HK40035689A (en) Pharmacophore for trail induction
NZ717556A (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220804

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20250110

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260320

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260320

C13 Application revived following an application revival request

Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS

Effective date: 20260504

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260504

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260504

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260504

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260504

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260507